Moderate/severe chronic kidney disease in women undergoing TAVR was associated with a greater risk of 1-year VARC-2 safety endpoints (HR 1.68; 95% CI 1.10-2.60) and all-cause death.
Observational (n=852)
Sí
Does moderate/severe chronic kidney disease increase the risk of mortality and morbidity in women undergoing TAVR?
In women undergoing TAVR, moderate to severe chronic kidney disease is independently associated with a significantly higher risk of 1-year mortality and VARC-2 safety endpoints.
Hazard Ratio: 1.68 (95% CI 1.1–2.6)
Abstract Background The prevalence of both chronic kidney disease (CKD) and aortic stenosis (AS) increase with age. Although baseline CKD is frequent in patients undergoing transcatheter aortic valve replacement (TAVR), its significance among women is largely unknown. Methods Women's INternational Transcatheter Aortic Valve Implantation (WIN‐TAVI) is a multinational, prospective registry of women undergoing TAVR for severe AS. We included patients with available baseline estimated glomerular filtration rate (eGFR) and completed 1‐year follow‐up. Patients were categorized into three groups based on their eGFR: No CKD (normal kidney function to stage 2 CKD: eGFR ≥60 ml/min/1.73 m 2 ); (b) mild CKD (stage 3a CKD: eGFR = 45–59 ml/min/1.73 m 2 ); and (c) moderate/severe CKD (stage ≥3b CKD: eGFR <45 ml/min/1.73 m 2 ). All events were adjudicated according to the Valve Academic Research Consortium (VARC)‐2 criteria. Result Out of 852 women undergoing TAVR, 326 (38.3%) had no CKD, 225 (26.4%) had mild CKD, and 301 (35.3%) had moderate/severe CKD. Women with higher stage of CKD at baseline were more likely to have a history of hypertension, diabetes, atrial fibrillation, anemia, chronic lung disease, hemodialysis, prior percutaneous coronary intervention, and pacemaker implantation. After multivariate adjustment, moderate/severe CKD was associated with a greater risk of 1‐year VARC‐2 safety endpoints hazard ratio (HR) 1.68, 95% confidence interval (CI): 1.10–2.60, all‐cause death (HR 2.00, 95% CI: 1.03–3.90), and composite of death, myocardial infarction, stroke or life‐threatening bleeding (HR 1.70, 95% CI: 1.04–2.76). There were no differences in 30‐day and 1‐year VARC‐2 efficacy and 30‐day VARC‐2 safety outcomes. Conclusion CKD is associated with substantial and independent risk for mortality and morbidity at 1‐year follow‐up in women undergoing TAVR.
Bandyopadhyay et al. (Fri,) conducted a observational in Severe aortic stenosis (n=852). Moderate/severe chronic kidney disease (eGFR <45 ml/min/1.73 m2) vs. No CKD or mild CKD was evaluated on 1-year VARC-2 safety endpoints (HR 1.68, 95% CI 1.10-2.60). Moderate/severe chronic kidney disease in women undergoing TAVR was associated with a greater risk of 1-year VARC-2 safety endpoints (HR 1.68; 95% CI 1.10-2.60) and all-cause death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: